ABL1 and breast cancer: One in vivo study examining whether lidocaine may act via inhibition of the Src oncogene studied the combination of i.v. lidocaine and bosutinib (a BCR-ABL, Src tyrosine kinase inhibitor) on metastatic outcomes after excision of primary tumours in a mouse model of breast cancer.31